A Randomized, Double-blind, Single-dosing, 2-way Cross-over Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 (Etanercept) 25mg With Those of Enbrel 25mg After Subcutaneous Injection in Healthy Male Volunteers

Trial Profile

A Randomized, Double-blind, Single-dosing, 2-way Cross-over Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 (Etanercept) 25mg With Those of Enbrel 25mg After Subcutaneous Injection in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2015

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors LG Life Sciences
  • Most Recent Events

    • 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 18 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 12 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top